OakChart

Rein Therapeutics Inc

RNTXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 11:13 AM ET

0.5917+0.0017 (0.29%)
2026-11-11 17:14 CET
Market cap
50.90 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-49.76 USD m
Free cash flow, TTM
-18.83 USD m
EPS diluted, TTM
-1.72
P/E
-
Compare

Price

RNTX against its 20, 50 and 200-day averages
2050200missearnings
0.500.751.001.251.501.2M2.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RNTXclose 0.5920-day 0.6350-day 0.72200-day 1.010.5952w low

71.8% under the 52-week high of 2.10 on 22 Apr 2026. 52-week low 0.54 on 14 Oct 2026. Last 15 sessions, 34.2% high to low

Profile

RNTX
52-week range, 3% of the way up
0.542.10

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Employees10
IPOJun 29, 2017
Beta1.45
ATR, 14d0.07
Rel volume1.21
Short float0.90%
Insider own8.49%
Inst own49.12%

Snapshot

6 groups

Valuation

Index-
Market Cap51.05M
Enterprise Value55.41M
Income-49.76M
Sales0.00M
Book/sh0.12
Cash/sh0.47
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPOJun 29, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.98
P/C1.26
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.27
Current Ratio4.27
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.72
EPS next Y-0.47
EPS next Q-0.10
EPS this Y76.53%
EPS next Y-1.09%
EPS next 5Y32.79%
EPS past 3/5Y31.21% 30.56%
Sales past 3/5Y- -
EPS Y/Y TTM36.23%
Sales Y/Y TTM-
EPS Q/Q66.32%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.41.18% -

Ownership

Insider Own8.49%
Insider Trans0.99%
Inst Own49.12%
Inst Trans48.96%
ROA-80.62%
ROE-96.42%
ROIC-90.14%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.81%
SMA50-17.96%
SMA200-41.46%
Trades-

Technical

Shs Outstand85.77M
Shs Float78.95M
Short Float0.90%
Short Ratio1.69
Short Interest0.71M
52W High2.10 -71.82%
52W Low0.54 9.55%
Volatility11.87% 12.56%
ATR (14)0.07
RSI (14)40.57
Beta1.45
Rel Volume1.21
Avg Volume419.36K
Volume154,017

Performance

Perf Week-10.17%
Perf Month-21.59%
Perf Quarter-24.86%
Perf Half Y-48.99%
Perf YTD-48.99%
Perf Year-60.29%
Perf 3Y-66.76%
Perf 5Y-96.80%
Perf 10Y-
Recom1.00
Target Price6.00
Prev Close0.59
Price0.59
Change %0.29%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Sep 22, 2025InitiatedHH.C. WainwrightBuy$10+1,590.0%
Jan 28, 2025InitiatedRRodman & RenshawBuy$8+1,252.0%
Jul 24, 2017InitiatedWWilliam BlairOutperform
Jul 24, 2017InitiatedJJefferiesBuy$20+3,280.1%
Jul 24, 2017InitiatedBBofA/MerrillBuy$19+3,111.1%

Peers

Mkt cap
TickerCompanyMkt cap
PLRXPliant Therapeutics Inc47.16M
VCREVicore Pharma Holding AB ADR317.93M
AVLNAvalyn Pharma Inc1.39B
TVRDTvardi Therapeutics Inc17.28M
GYREGyre Therapeutics Inc492.26M
SKYESkye Bioscience Inc3.71M
SVRASavara Inc1.14B
GALTGalectin Therapeutics Inc341.37M
PULMPulmatrix Inc4.78M
IVAInventiva ADR931.29M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
VON RICKENBACH JOSEF HDirectorMay 26 '26Buy1.0623,19024,47058,014May 28 08:15 PM
VON RICKENBACH JOSEF HDirectorMay 22 '26Buy1.0515,95016,70834,824May 28 08:15 PM
VON RICKENBACH JOSEF HDirectorMay 27 '26Buy1.074,5004,81962,514May 28 08:15 PM
VON RICKENBACH JOSEF HDirectorMay 21 '26Buy1.043,4203,56418,874May 28 08:15 PM
WINDSOR JAMES BRIANSee RemarksApr 30 '26Buy1.0025,00025,00027,046May 13 08:47 AM
Voss Capital, LP10% OwnerNov 14 '25Buy1.22104,183127,593926,441Nov 18 05:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B

News

latest 14 of 206
  • Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) -5.16%
  • Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress (GlobeNewswire) +5.39%
  • Rein Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +8.88%
  • Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
  • Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Loading…
  • Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications (GlobeNewswire)
  • Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries (GlobeNewswire) +6.02%
  • Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom (GlobeNewswire)
  • Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
  • Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +6.27% -23.99%
  • Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire) -12.07%
  • Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis (GlobeNewswire)
  • Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.100-0.170-0.1000.000.002
2026Q12026-05-20-0.190-0.490-0.1920.000.001
2025Q42026-04-06-1.090-1.090-1.2190.000.001
2025Q32025-11-14-0.210-0.240-0.2120.000.002
2025Q22025-08-06-0.280-0.220-0.2820.000.001
2025Q12025-05-15-0.250-0.210-0.2510.000.001
2024Q42025-04-07-1.890-0.300-1.8920.000.002
2024Q32024-11-14-0.270-0.245-0.2700.000.002
2024Q22024-08-20-0.450-0.306-0.4490.000.002
2024Q12024-05-15-0.860-0.140-0.8570.000.001
2023Q42024-04-15-1.540-0.164-1.539-0.001
2022Q32022-11-01-1.400-1.650-1.4020.000.004
2022Q22022-08-15-1.800-1.700-1.7600.000.004
2022Q12022-05-05-1.800-1.533-1.8580.000.003
2021Q42022-03-28-1.600-1.600-1.5010.000.003
2021Q32021-11-12-1.400-1.400-1.4810.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-24.000-24.600-23.9400.000.00
2020FY-12.200-12.200-12.1360.000.00
2021FY-5.800-6.000-5.8920.000.00
2022FY-6.400-6.400-6.0210.000.00
2023FY-3.420--3.4210.00-
2024FY-3.510-1.745-3.5050.000.00
2025FY-1.960-1.445-3.4200.000.00
2026FY--0.460--0.00
2027FY--0.465--0.00
2028FY--0.595--0.00
2029FY--0.580--0.00
2030FY--0.050--144.1

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-201000.000.000.00
2026Q3S2026-04-061000.000.000.00
2026Q3S2026-04-011000.000.000.00
2026Q3R2026-10-31100-0.10-0.10-0.10
2026Q3R2026-08-17101-0.10-0.10-0.10
2026Q3R2026-08-14100-0.08-0.08-0.08
2026Q3R2026-07-17100-0.08-0.08-0.08
2026Q3E2026-10-31200-0.10-0.10-0.10
2026Q3E2026-08-17201-0.10-0.10-0.10
2026Q3E2026-08-14200-0.09-0.10-0.08
2026Q3E2026-08-12200-0.09-0.10-0.08
2026Q3E2026-07-17210-0.09-0.10-0.08
2026Q3E2026-05-29110-0.10-0.10-0.10

Estimate history

EPS, annual-60.8-42.81-23.94-12.136-5.892-6.021-3.421-3.505-1.96-1.7183
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.449-0.27-1.892-0.251-0.282-0.212-1.219-0.192-0.095
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.7360.7371.3912.194.5294.5414.88621.66627.5585.767
Period201720182019202020212022202320242025MRQ
Shares, quarterly21.62521.66621.66622.00523.04625.1427.5528.03985.767
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.060.120.170.120.160.150.22
Gross Profit0.00-0.00-0.06-0.12-0.17-0.12-0.16-0.15-0.22
Selling, General and Administrative Excl. Other20.7621.9328.0515.2327.4826.4820.3329.8031.68
Research and Development10.3911.0314.253.9917.9717.0111.1717.6618.45
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-20.76-21.93-28.11-15.35-27.65-26.61-20.50-29.96-31.90
Interest Expense-0.000.000.000.00--0.00-
Unusual Expense28.7028.7037.000.93-0.32-0.380.00--
Net Income Before Taxes-50.47-50.58-64.43-15.73-27.33-26.16-21.16-29.37-31.55
Income Taxes-0.71-0.71-1.540.000.000.000.000.000.00
Consolidated Net Income-49.76-49.87-62.88-15.73-27.33-26.16-21.16-29.37-31.55
Net Income From Continuing Operations-49.76-49.87-62.88-15.73-27.33-26.16-21.16-29.37-31.55
Net Income-49.76-49.87-62.88-15.73-27.33-26.16-21.16-29.37-31.55
EPS (Recurring)-0.44-1.17-2.06-3.28-6.07-5.95-12.14-23.94-42.81
EPS (Basic, Before Extraordinaries)-1.72-1.96-3.51-3.42-6.02-5.89-12.14-23.94-42.81
EPS (Diluted)-1.72-1.96-3.51-3.42-6.02-5.89-12.14-23.94-42.81
EBITDA-20.76-21.93-28.05-15.23-27.48-26.48-20.33-29.80-31.68
Non-Operating Income (Expense)-1.020.050.690.540.000.07-0.660.590.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-1.760.881.192.082.261.892.123.28
Shares Outstanding85.7727.5521.674.894.544.532.191.390.74
Market Capitalization50.9050.9049.8314.8910.7650.9845.5615.9412.39

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.00-0.000.000.000.00
Selling, General and Administrative Excl. Other6.085.233.965.496.875.615.806.07
Research and Development3.643.072.001.684.293.053.323.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.08-5.23-3.96-5.49-6.87-5.61-5.80-6.07
Interest Expense0.00-0.000.000.000.000.000.00
Unusual Expense0.000.0028.700.000.000.0037.000.00
Net Income Before Taxes-6.38-5.84-32.68-5.58-6.82-5.50-42.52-5.85
Income Taxes0.000.00-0.710.000.000.00-1.540.00
Consolidated Net Income-6.38-5.84-31.97-5.58-6.82-5.50-40.98-5.85
Net Income From Continuing Operations-6.38-5.84-31.97-5.58-6.82-5.50-40.98-5.85
Net Income-6.38-5.84-31.97-5.58-6.82-5.50-40.98-5.85
EPS (Recurring)-0.10-0.19-0.45-0.21-0.28-0.25-0.70-0.27
EPS (Basic, Before Extraordinaries)-0.10-0.19-1.22-0.21-0.28-0.25-1.89-0.27
EPS (Diluted)-0.10-0.19-1.22-0.21-0.28-0.25-1.89-0.27
EBITDA-6.08-5.23-3.96-5.49-6.87-5.61-5.80-6.07
Non-Operating Income (Expense)-0.30-0.61-0.02-0.090.050.110.270.22
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.160.16-1.450.260.260.110.51
Shares Outstanding85.7728.0427.5525.1423.0522.0121.6721.67
Market Capitalization50.9036.4530.4926.9631.0238.3549.8376.70

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.2112.8717.3421.2745.9614.4018.3020.7250.84
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.110.790.930.612.221.931.251.051.00
Total Current Assets4.3313.6618.2721.8748.1816.3319.5521.7751.84
Net Property, Plant & Equipment0.000.000.020.110.280.016.367.290.15
Total Investments and Advances0.000.000.000.000.000.000.570.570.00
Intangible Assets19.8348.5385.53--0.000.00--
Deferred Tax Assets2.237.0513.28---1.65--
Other Assets0.000.002.190.020.020.000.000.680.69
Total Assets26.3969.24119.2922.0148.4816.3428.1230.3152.69
Short Term Debt Incl. Current Port. of LT Debt0.000.000.050.030.090.170.450.000.00
Accounts Payable3.980.911.191.721.211.601.451.731.60
Other Current Liabilities2.204.843.151.633.212.203.943.643.29
Total Current Liabilities6.185.754.383.384.513.965.845.374.89
Long Term Debt0.000.000.000.000.070.224.595.340.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities3.298.8216.60---1.65--
Other Liabilities0.000.280.000.000.000.000.000.000.00
Total Liabilities9.4714.8520.993.384.584.1812.0710.714.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value45.0145.0191.410.000.000.000.000.000.00
Common Equity-28.099.396.8918.6243.9012.1616.0519.6047.80
Total Shareholders Equity16.9254.3998.3018.6243.9012.1616.0519.6047.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity16.9254.3998.3018.6243.9012.1616.0519.6047.80
Total Liabilities & Stockholders Equity26.3969.24119.2922.0148.4816.3428.1230.3152.69
Book Value Per Share-1.020.431.414.109.695.5511.5426.5864.92
Tangible Book Value Per Share-1.74-1.81-16.104.109.695.5511.5426.5864.92
Full-Time Employees1011156981323-
Price to Book Ratio4.960.991.240.471.163.750.990.632.87
Return on Assets-104.31-66.71-22.27-77.54-80.73-95.17-100.52-76.02-60.51
Return on Equity-139.87-82.37-26.91-87.42-93.33-150.00-164.77-93.62-68.77
Return on Invested Capital-294.78-115.61-16.00-146.75-59.50-170.88-142.33-126.48-47.29
Quick Ratio0.702.384.176.4610.694.123.354.0510.60
Current Ratio0.702.384.176.4610.694.123.354.0510.60

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-49.76-49.87-62.88-15.73-27.33-26.16-21.16-29.37-31.55
Depreciation-0.000.060.120.170.120.160.150.22
Other Funds (Non Cash)32.6731.3738.121.191.882.051.801.893.02
Funds from Operations-17.09-18.50-24.70-14.43-25.29-24.00-19.20-27.32-28.31
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.74-0.862.41-5.380.420.24-1.280.850.39
Cash from Operating Activities-18.83-19.36-22.29-19.81-24.86-23.75-20.48-26.47-27.93
Capital Expenditures-2.980.000.000.000.00-0.16-0.01-0.15-4.42
Net Assets From Acquisitions0.000.000.00-0.100.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.040.000.070.210.00-
Purchase or Sale of Investments-32.090.000.0016.2526.46-35.836.21-2.6629.11
Purchase of Investments-32.090.000.000.00-21.85-73.58-10.03-27.24-31.19
Sale Or Maturity of Investments0.000.000.0016.2548.3137.7516.2424.5760.30
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-35.070.000.0016.2026.46-35.926.41-2.8124.69
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock57.859.7617.820.000.0055.6615.4123.960.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock57.859.7617.820.000.0055.6615.4123.960.04
Proceedsfrom Stock Options57.854.6710.640.000.0055.5815.4123.800.00
Issuance or Reduction of Debt, Net-1.070.000.000.000.000.000.390.002.47
Change in Long Term Debt0.000.000.000.000.000.000.390.002.47
Issuance of Long Term Debt0.000.000.000.000.000.000.390.002.47
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.0015.790.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities56.779.7617.8215.790.0055.6615.8023.962.52
Exchange Rate Effect--0.040.00-0.06-----
Net Change in Cash2.82-9.65-4.4712.121.59-4.011.74-5.32-0.72
Free Cash Flow-18.83-19.36-22.29-19.81-24.86-23.91-20.48-26.62-32.35
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments40.654.453.214.055.727.43
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.811.011.111.130.880.90
Total Current Assets41.455.454.335.176.608.33
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances2.980.000.000.000.000.00
Intangible Assets19.8319.8319.8348.5348.5348.53
Deferred Tax Assets--2.23---
Other Assets1.711.000.000.002.350.77
Total Assets65.9726.2926.3953.7157.4857.63
Short Term Debt Incl. Current Port. of LT Debt0.004.920.000.000.000.00
Accounts Payable4.476.263.984.126.031.15
Other Current Liabilities5.242.452.201.621.674.83
Total Current Liabilities9.7113.646.185.747.695.98
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.061.063.291.771.771.77
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.7714.709.477.529.477.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value45.0145.0145.0145.0145.0145.01
Common Equity10.20-33.41-28.091.193.014.87
Total Shareholders Equity55.2011.5916.9246.1948.0149.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity55.2011.5916.9246.1948.0149.88
Total Liabilities & Stockholders Equity65.9726.2926.3953.7157.4857.63
Book Value Per Share0.12-1.19-1.020.050.130.22
Tangible Book Value Per Share-0.11-1.90-1.74-1.88-1.98-1.98
Full-Time Employees--10---
Price to Book Ratio4.96-1.2824.618.776.320.76
Return on Assets-80.62-119.66-104.31-74.57-70.89-78.14
Return on Equity-96.42-163.36-139.87-83.28-79.38-86.78
Return on Invested Capital-11.55-50.37-188.95-12.08-14.21-11.03
Quick Ratio4.270.400.700.900.861.39
Current Ratio4.270.400.700.900.861.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.38-5.84-31.97-5.58-6.82-5.50
Depreciation--0.000.000.000.00
Other Funds (Non Cash)1.030.7829.011.850.260.26
Funds from Operations-5.34-5.06-2.96-3.73-6.57-5.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.301.64-0.260.190.15-0.94
Cash from Operating Activities-8.64-3.42-3.22-3.55-6.42-6.17
Capital Expenditures-2.980.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-32.090.000.000.000.000.00
Purchase of Investments-32.090.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-35.070.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock53.190.354.300.004.710.74
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock53.190.354.300.004.710.74
Proceedsfrom Stock Options53.190.354.300.00-0.370.74
Issuance or Reduction of Debt, Net-5.384.300.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-1.901.900.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities47.814.652.401.904.710.74
Exchange Rate Effect---0.02-0.03--
Net Change in Cash4.101.23-0.83-1.67-1.71-5.44
Free Cash Flow-8.64-3.42-3.22-3.55-6.42-6.17

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.90%0.7M79.0M429.49K
2026-10-150.75%0.6M79.0M449.76K
2026-09-300.82%0.7M79.0M417.20K
2026-09-150.85%0.7M79.0M503.42K
2026-08-310.82%0.6M78.9M506.55K
2026-08-140.93%0.7M78.9M497.58K
2026-07-311.11%0.9M79.0M840.96K
2026-07-151.11%0.9M79.0M805.19K
2026-06-301.14%0.9M79.0M763.25K
2026-06-150.39%0.3M80.1M640.99K
2026-05-290.49%0.4M79.5M577.16K
2026-05-150.53%0.4M79.6M519.61K
2026-04-303.83%0.8M21.8M126.58K
2026-04-150.90%0.2M26.3M112.02K
2026-03-311.86%0.5M26.2M105.76K
2026-03-131.82%0.4M24.6M138.59K
2026-02-271.82%0.4M24.6M166.03K
2026-02-131.78%0.4M24.6M183.55K
2026-01-301.80%0.4M24.6M970.92K
2026-01-151.43%0.4M24.6M967.16K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-048-KCurrent report2026-09-04SEC
2026-08-278-KCurrent report2026-08-21SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-07-218-KCurrent report2026-07-20SEC
2026-07-14SCHEDULE 13G/ASEC
2026-06-08ARSAnnual report to security holders. 2025-12-31SEC
2026-06-08DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-08DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-20SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-28PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-20SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-08SCHEDULE 13G/ASEC
2026-05-08SCHEDULE 13GSEC
2026-05-07SCHEDULE 13GSEC
2026-05-06SCHEDULE 13GSEC
2026-05-048-KCurrent report2026-04-30SEC
2026-05-04424B5SEC
2026-04-30EFFECTEffectiveness filing by commission orderSEC
2026-04-28CORRESPSEC
2026-04-28CORRESPSEC
2026-04-28S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-04-2710-K/A2025-12-31SEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-028-KCurrent report2026-02-24SEC
2026-02-198-KCurrent report2026-02-16SEC
2026-02-13SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0549.56K400
2026-0425.00K100
2026-030000
2026-020000
2026-010000
2025-120000
2025-11127.59K100

Institutional holders

Manager% owned
Voss Capital, LP6.15%
Cable Car Capital, LP6.07%
ADAR1 Capital Management, LLC5.26%
VANGUARD CAPITAL MANAGEMENT LLC3.95%
BIOS Capital Management, LP3.49%
Ikarian Capital, LLC3.45%
GREAT POINT PARTNERS LLC3.01%
CITADEL ADVISORS LLC2.85%
Velan Capital Investment Management LP1.99%
Senvest Management, LLC1.44%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.95%
VANGUARD EXTENDED MARKET INDEX FUND0.92%
Fidelity Extended Market Index Fund0.43%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.12%
iShares Micro-Cap ETF0.10%
Fidelity Nasdaq Composite Index ETF0.09%
VANGUARD BALANCED INDEX FUND0.05%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.03%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. RNTX. Cached 15 minutes.